Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Excler

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 1997
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteersG Ferrari, W Humphrey, M J McElrath, et al.
AIDS Research and Human Retroviruses|March 1, 1995
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDAG Pialoux, J L Excler, Y Rivière, et al.
AIDS Research and Human Retroviruses|December 1, 1995
Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteersD Salmon-Céron, J L Excler, D Sicard, et al.
AIDS (London, England)|January 6, 1999
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation GroupR B Belshe, G J Gorse, M J Mulligan, et al.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
AIDS Research and Human Retroviruses|May 20, 1999
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le SidaD Salmon-Céron, J L Excler, L Finkielsztejn, et al.
The Journal of Infectious Diseases|April 1, 1997
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccinesS Zolla-Pazner, C Alving, R Belshe, et al.
The Journal of Infectious Diseases|April 11, 2001
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe, C Stevens, G J Gorse, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 1997
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteersG Ferrari, W Humphrey, M J McElrath, et al.
AIDS Research and Human Retroviruses|March 1, 1995
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDAG Pialoux, J L Excler, Y Rivière, et al.
AIDS Research and Human Retroviruses|December 1, 1995
Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteersD Salmon-Céron, J L Excler, D Sicard, et al.
AIDS (London, England)|January 6, 1999
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation GroupR B Belshe, G J Gorse, M J Mulligan, et al.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
AIDS Research and Human Retroviruses|May 20, 1999
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le SidaD Salmon-Céron, J L Excler, L Finkielsztejn, et al.
The Journal of Infectious Diseases|April 1, 1997
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccinesS Zolla-Pazner, C Alving, R Belshe, et al.
The Journal of Infectious Diseases|April 11, 2001
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe, C Stevens, G J Gorse, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Pageof 4